Amal Therapeutics is a Geneva, Switzerland–based pre-clinical biotechnology company developing peptide- and protein-based therapeutic cancer vaccines. Its programs are built on a proprietary KISIMA® self-adjuvanting protein-based immunization platform. The company's lead programme, ATP128, is a therapeutic protein vaccine targeting metastatic colorectal cancer and was expected to enter Phase I clinical trials in 2019. Amal plans to use recent funding to progress ATP128 toward clinical development and proof-of-concept in colorectal cancer, with a clinical trial anticipated to start in summer 2019. The company also intends to further develop the KISIMA platform to produce single therapeutic vaccines for immunotherapy and beyond. Amal is led by CEO and founder Dr Madiha Derouazi. AMAL Therapeutics is a Geneva-based Swiss biotech spun out from the University of Geneva and incorporated in September 2012. The company develops peptide-based therapeutic cancer vaccines built on its proprietary KISIMA platform, which combines a cell-penetrating peptide, multi-antigenic chimeric cargo and a toll-like receptor agonist. Its lead product candidate is ATP128, targeted at colorectal cancer. AMAL's preclinical data showed potent, multi-antigenic, long-lasting anti-tumour immunity and prevention of tumour immune escape. The company plans to use newly raised funds to progress ATP128 into clinical studies and to further develop the KISIMA platform across additional oncology indications. The firm remains privately held and advancing toward clinical proof-of-concept. Amal Therapeutics is a biotech spin-off from the University of Geneva developing therapeutic cancer vaccines based on its KISIMA technology platform. The company combines a Cell Penetrating Peptide (CPP) with a multi-antigenic chimeric cargo containing CD8+ and CD4+ epitopes and a constitutive dendritic cell activator to stimulate multi-epitopic cytotoxic T cell responses, helper T cells and immunological memory. Amal is in preclinical development with its lead vaccine candidate ATP124 for colorectal cancer and is advancing the broader KISIMA platform to generate long-lasting anti-tumor immunity and avoid tumor immune escape. The company was incorporated in 2012 as a University of Geneva spin-off and is led by CEO Dr. Madiha Derouazi. Amal intends to use the proceeds from its recent financing to progress its cancer vaccine programs. Amal Therapeutics develops therapeutic cancer vaccines based on a proprietary cell-penetrating peptide platform. The company was founded in 2012 by Madiha Derouazi as a spin‑out from the University of Geneva and is based in Geneva and Berlin. It intends to use recent seed funding to consolidate its peptide-based technology platform. Amal plans to progress its first vaccine candidate up to pre-clinical development. The company recently closed a seed round (amount undisclosed) led by Boehringer Ingelheim Venture Fund with participation from High‑Tech Gründerfonds. As part of the financing, Dr. Knut Elbers of BIVF joined Amal’s board of directors.

Total raised

$36M

Funding rounds

4

Latest round

Series B

Latest activity

Nov 2018